Acknowledgement
Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1F1A1067569) supported this work. Thank you for the Undergraduate Research Program (URP) grant of Kyung Hee University College of Korean Medicine, Republic of Korea.
References
- Michaelis R, Tang V, Nevitt SJ, Wagner JL, Modi AC, LaFrance WC Jr, et al. Psychological treatments for people with epilepsy. Cochrane Database Syst Rev. 2020;8(8):CD012081.
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-9. https://doi.org/10.1056/NEJM200002033420503
- Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology. 2013;80(6):590-9. https://doi.org/10.1212/WNL.0b013e31827b1ae0
- Kennedy SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci. 2008;10(3):271-7. https://doi.org/10.31887/DCNS.2008.10.3/shkennedy
- Kanner AM. Depression and epilepsy: a bidirectional relation? Epilepsia. 2011;52 Suppl 1:21-7. https://doi.org/10.1111/j.1528-1167.2010.02907.x
- Danzer SC. Depression, stress, epilepsy and adult neurogenesis. Exp Neurol. 2012;233(1):22-32. https://doi.org/10.1016/j.expneurol.2011.05.023
- Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72(2):184-91. https://doi.org/10.1002/ana.23601
- Quigg M, Gharai S, Ruland J, Schroeder C, Hodges M, Ingersoll KS, et al. Insomnia in epilepsy is associated with continuing seizures and worse quality of life. Epilepsy Res. 2016;122:91-6. https://doi.org/10.1016/j.eplepsyres.2016.02.014
- Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48(12):2336-44. https://doi.org/10.1111/j.1528-1167.2007.01222.x
- Macedo PJOM, Oliveira PS, Foldvary-Schaefer N, Gomes MDM. Insomnia in people with epilepsy: a review of insomnia prevalence, risk factors and associations with epilepsy-related factors. Epilepsy Res. 2017;135:158-67. https://doi.org/10.1016/j.eplepsyres.2017.05.014
- Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: observations from prospective audits. Epilepsy Behav. 2017;71(Pt A):73-8. https://doi.org/10.1016/j.yebeh.2017.04.003
- Zhang LL, Zeng LN, Li YP. Side effects of phenobarbital in epilepsy: a systematic review. Epileptic Disord. 2011;13(4):349-65. https://doi.org/10.1684/epd.2011.0444
- Foldvary N, Perry M, Lee J, Dinner D, Morris HH. The effects of lamotrigine on sleep in patients with epilepsy. Epilepsia. 2001;42(12):1569-73. https://doi.org/10.1046/j.1528-1157.2001.46100.x
- Trivedi MH, Kurian BT. Managing depressive disorders in patients with epilepsy. Psychiatry (Edgmont). 2007;4(1):26-34.
- Maguire MJ, Weston J, Singh J, Marson AG. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev. 2014;2014(12):CD010682.
- Guo Y, Ding XY, Lu RY, Shen CH, Ding Y, Wang S, et al. Depression and anxiety are associated with reduced antiepileptic drug adherence in Chinese patients. Epilepsy Behav. 2015;50:91-5. https://doi.org/10.1016/j.yebeh.2015.06.042
- Curran S, de Pauw K. Selecting an antidepressant for use in a patient with epilepsy. Safety considerations. Drug Saf. 1998;18(2):125-33. https://doi.org/10.2165/00002018-199818020-00004
- Gilliam FG, Black KJ, Carter J, Freedland KE, Sheline YI, Tsai WY, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Ann Neurol. 2019;86(4):552-60. https://doi.org/10.1002/ana.25561
- Wani M, Polshettiwar SA, Parakh SR, Chopade VV. Herbal medicine and its standardization. Pharm Rev. 2007;5(6):1-2.
- Sun X, Chen A, Xu X, Zhang H, Tang Q, Zhang H. Randomized, double blind, placebo-controlled trial of Shuganjieyu capsule in the treatment of mild or moderate depression. Chin J New Drugs. 2009;18:413-6.
- Si C, Wang H, Luo M, Xie J, Chen Y, Guan H, et al. A control study on treatment of vasovagal syncope with mild-to-moderate depression and anxiety by Shugan Jieyu capsules, Flupentixol and Melitracen tablets. World Sci Technol Mod Tradit Chin Med. 2015;17(6):1230-4.
- Deng H, Adams CE. Traditional Chinese medicine for schizophrenia: a survey of randomized trials. Asia Pac Psychiatry. 2017;9(1):e12265.
- Fan M, Guo D, Tian Y, Liu Y, Zhao J. Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(8):e24856.
- Gong L, Yang X, Feng Y, Fei Z, Wang M, Qin B, et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke - a randomized clinical trial. Eur J Integr Med. 2020;35:101102.
- Yao G, Li J, Wang J, Liu S, Li X, Cao X, et al. Improved restingstate functional dynamics in post-stroke depressive patients after Shugan Jieyu capsule treatment. Front Neurosci. 2020;14:297.
- Li W, Liu M, Feng S, Wu B, Zhang S, Yang W, et al. Acanthopanax for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(3):CD007032.
- Zhang X, Kang D, Zhang L, Peng L. Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review. Aging Ment Health. 2014;18(8):941-53. https://doi.org/10.1080/13607863.2014.899975
- Kuo J, Chen KW, Cheng IS, Tsai PH, Lu YJ, Lee NY. The effect of eight weeks of supplementation with Eleutherococcus senticosus on endurance capacity and metabolism in human. Chin J Physiol. 2010;53(2):105-11. https://doi.org/10.4077/CJP.2010.AMK018
- Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John's wort) in depression: a meta-analysis. J Affect Disord. 2017;210:211-21. https://doi.org/10.1016/j.jad.2016.12.048
- Rezaei A, Rezaei-Dorostkar K, Pashazadeh M, Ahmadizadeh C, Jafari B. A comparative study of sedative and anxiolytic effects of the Hypericum perforatumin and diazepam on rats. Zahedan J Res Med Sci. 2012;13(8):e93758.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.